Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)
Fredrik Schjesvold, Meletios A Dimopoulos, Sosana Delimpasi, Paweł Robak, Daniel Coriu, Wojciech Legieć, Luděk Pour, Ivan Špıčka, Tamás Masszi, Vadim Doronin, Jiří Minařík, Galina Salogub, Yulia Alexeeva, Antonio Lazzaro, Vladimír Maisnar, Gábor Mikala, Stefan Norin, Marcus Thuresson, A. Bergan, Jakob Obermüller, Roman Hájek, María‐Victoria Mateos, Paul G. Richardson, Pieter Sonneveld (2023). Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM). , 142(Supplement 1), DOI: https://doi.org/10.1182/blood-2023-177945.
Article34 days agoLong-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)
Fredrik Schjesvold, Meletios A Dimopoulos, Sosana Delimpasi, Paweł Robak, Daniel Coriu, Wojciech Legieć, Luděk Pour, Ivan Špıčka, Tamás Masszi, Vadim Doronin, Jiří Minařík, Galina Salogub, Yulia Alexeeva, Antonio Lazzaro, Vladimír Maisnar, Gábor Mikala, Stefan Norin, Marcus Thuresson, A. Bergan, Jakob Obermüller, Roman Hájek, María‐Victoria Mateos, Paul G. Richardson, Pieter Sonneveld (2023). Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM). , 142(Supplement 1), DOI: https://doi.org/10.1182/blood-2023-177945.
Article34 days agoLong-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)
Fredrik Schjesvold, Meletios A Dimopoulos, Sosana Delimpasi, Paweł Robak, Daniel Coriu, Wojciech Legieć, Luděk Pour, Ivan Špıčka, Tamás Masszi, Vadim Doronin, Jiří Minařík, Galina Salogub, Yulia Alexeeva, Antonio Lazzaro, Vladimír Maisnar, Gábor Mikala, Stefan Norin, Marcus Thuresson, A. Bergan, Jakob Obermüller, Roman Hájek, María‐Victoria Mateos, Paul G. Richardson, Pieter Sonneveld (2023). Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM). , 142(Supplement 1), DOI: https://doi.org/10.1182/blood-2023-177945.
Article34 days agoOral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial
Meletios A Dimopoulos, Fredrik Schjesvold, Vadim Doronin, Olga Vinogradova, Hang Quach, Xavier Leleu, Yolanda González Montes, Karthik Ramasamy, Alessandra Pompa, Mark‐David Levin, Cindy Lee, Ulf Henrik Mellqvist, Roland Fenk, Hélène Demarquette, Hamdi Sati, Alexander Vorog, Richard Labotka, Jichang Du, Mohamed Darif, Shaji Kumar (2022). Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial. , 12(1), DOI: https://doi.org/10.1038/s41408-021-00593-2.
Article34 days agoOAB-050: OCEAN (OP-103): a Phase 3, randomized, global, head-to-head comparison study of Melflufen and Dexamethasone (Dex) versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)
Fredrik Schjesvold, Meletios A Dimopoulos, Sosana Delimpasi, Pawef Robak, Daniel Coriu, Wojciech Legieć, Luděk Pour, Ivan Špıčka, Tamás Masszi, Vadim Doronin, Jiří Minařík, Galina Salogub, Yulia Alexeeva, Antonio Lazzaro, Vladimír Maisnar, Gábor Mikala, Victoria Moody, Marcus Thuresson, Catriona Byrne, Johan Harmenberg, Roman Hájek, María‐Victoria Mateos, Paul G. Richardson, Pieter Sonneveld (2021). OAB-050: OCEAN (OP-103): a Phase 3, randomized, global, head-to-head comparison study of Melflufen and Dexamethasone (Dex) versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM). , 21, DOI: https://doi.org/10.1016/s2152-2650(21)02124-8.
Article34 days ago